Metabolic longevity
Longevity medicine is only as good as its measurements. A useful evaluation starts with a broad biomarker panel — metabolic, inflammatory, lipid and hormonal — and works from what the data shows rather than from a fixed protocol.
What a provider evaluates
- Comprehensive metabolic panel and fasting insulin
- ApoB and a full lipid panel, rather than total cholesterol alone
- hs-CRP and other inflammatory markers
- HbA1c and markers of glycaemic control
- Hormonal markers appropriate to age and sex
What treatment may involve
- Metformin, where metabolic markers support it
- NAD+ therapy, noting it is compounded and not FDA-approved
- Targeted supplementation based on measured deficiency
- Repeat biomarker testing to review response
Whether any of these is appropriate is determined by a licensed provider after reviewing your history and laboratory results.
Medications a provider may consider
Markers on this panel
What each marker measures and why your provider tracks it.
Questions about metabolic longevity
What is NAD+ therapy?
NAD+ is a coenzyme central to cellular energy metabolism and DNA repair, and its levels decline with age. It is offered as a compounded preparation by subcutaneous injection or intravenous infusion. It is not FDA-approved for this use, clinical evidence for longevity outcomes in humans is limited, and protocols are not standardised. Infusion is commonly associated with flushing and discomfort, which is rate-dependent.
Which biomarkers matter most in longevity care?
The most informative markers tend to be metabolic and cardiovascular rather than exotic. ApoB gives a better picture of atherogenic risk than total cholesterol. Fasting insulin and HbA1c describe glycaemic control before overt disease. hs-CRP captures inflammatory burden. Beyond those, hormonal markers appropriate to your age and sex, and liver and kidney function to establish a baseline. What matters is tracking the same markers over time.